A new treatment for alopecia areata!

A new treatment for Alopecia Areata has been announced from Concert Pharmaceuticals and will begin clinical trials later this year! In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative meeting during the 2016-2017 fiscal year. In response, Concert Pharmaceuticals has developed and patented CTP-543, which will be in clinical trials as an oral treatment for alopecia areata later this year. To read the official announcement from Concert Pharmaceuticals, click here.